Meeting the Growth-Stage Investment Challenge

A critical funding gap exists for growth-stage bio-innovation companies positioned for significant revenue and EBITDA growth. Fundamentum Capital bridges this gap through our distinctive advisory structure, combining scientific, defence, and intelligence expertise to identify and accelerate the most promising opportunities in a range of areas.

Biomolecular Engineering

We fund technologies that reprogram nature's molecular machinery to pioneer new therapeutics and smart materials.

Biomachine Convergence

We invest in technologies bridging biological systems and machines, revolutionizing healthcare and consumer technologies through intelligent interfaces.

Sustainable Food Systems

We fund breakthrough biological technologies transforming agriculture and food production to meet global nutrition challenges.

Cellular and Molecular Mapping

We invest in breakthrough intracellular mapping technologies that unlock precision medicine and targeted cellular therapies.

Biocomputing Frontiers

We back technologies harnessing cellular machinery for computation, pioneering new frontiers in data storage and biological programming.

Advanced Materials and Energy

We invest in bio-engineered solutions revolutionizing sustainable materials and energy systems through nature-inspired innovation.

Biosystems Transformation

We back technologies that reengineer biological systems, pioneering advances in regenerative medicine and synthetic biology.

Health and Performance Enhancement

We invest in technologies converging biology and computation to unlock unprecedented human health and performance capabilities.